Tirzepatide Results, Explained: What the SURMOUNT Trials Actually Show

Fifteen percent. Nineteen and a half. Just under twenty-one. Those are the three numbers from the trial that got tirzepatide approved for weight loss. Each one belongs to a maintenance dose, not to a before-and-after photo. If you're deciding whether to start, or wondering if your first weeks are normal, they matter more than any post online.

How much weight do people actually lose on tirzepatide, on average?

SURMOUNT-1 is still the clearest guide. It followed 2,539 adults with obesity or overweight, without diabetes, for 72 weeks. On average, they lost 15.0% of their starting weight on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg. People on placebo, a dummy shot, lost 3.1%. Those averages count everyone assigned to a dose, even people who stopped early.

An average hides a wide spread. At least 5% of body weight, the usual bar for a drug "working," was reached by 85% of people on 5 mg, 89% on 10 mg and 91% on 15 mg. On placebo, 35% got there. At the high end, half the people on 10 mg and 57% on 15 mg lost 20% or more, against 3% on placebo. If you land under the average, you're not necessarily a non-responder. You're somewhere in a range most coverage never shows.

How long does tirzepatide take to start working?

It works in two stages. Appetite usually changes first. Food noise quiets, and smaller portions start to feel like enough, often within the first couple of weeks. The scale lags on purpose. Tirzepatide starts at 2.5 mg, a low dose meant to let your body adjust, not to cause weight loss.

A 2025 analysis of SURMOUNT-1 sorted people by how fast the scale moved. Among people who took most of their doses, 82% had lost at least 5% by week 12. The other 18% were slower. Still, 90% of them reached 5% by week 72, taking about 25 weeks on average. A slow first three months is common and doesn't predict failure.

What does a realistic month-by-month timeline look like?

Knowing the shape of the curve makes the slow start easier. The timeline below assumes the dose rises every four weeks. Staying longer on a step for side effects pushes everything later.

• Weeks 1 to 4, at 2.5 mg: appetite is usually the first thing to shift, while the scale barely moves.
• Week 12, about 3 months: in the 2025 analysis, 82% of people who took most doses had lost at least 5%. Most of the rest caught up later.
• Around 6 months: reaching 15 mg takes at least 20 weeks, so many people are still stepping up and still losing.
• 6 to 9 months: among people who lost at least 5%, half had reached their plateau by about 6 to 8 months, depending on starting BMI.
• 72 weeks, about 17 months: SURMOUNT-1's headline results, about 15%, 19.5% and 21% by dose.
• 3 years: in people who also had prediabetes, weight loss at 176 weeks was 12.3%, 18.7% and 19.7% by dose, against 1.3% on placebo. Most of the loss held.

What do real before-and-after numbers show?

Strip away the marketing, and "before and after" means three groups. A minority lose under 5% and are called non-responders. In SURMOUNT-1, that was about one in ten people on 10 or 15 mg. Most land in a middle band. And about half of people on 10 or 15 mg lost 20% or more.

None of these groups is a verdict on effort. Results depend on the dose you reach, on biology you can't see on an intake form, and on taking the shot every week. A photo can't show any of that. A number tied to a week and a dose can.

How does tirzepatide work for weight loss?

Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, instead of the single one older drugs target. The GLP-1 side quiets hunger signals in the brain. It slows how fast the stomach empties, so a normal meal keeps you full longer. It also prompts insulin only when blood sugar is high. GIP, the second hormone, appears to add to the effect on appetite and blood sugar. Researchers are still working out how much of tirzepatide's edge comes from it.

In practice, the appetite effect does most of the visible work. Less hunger and earlier fullness move the scale without a strict diet. The mechanism is hormonal, not willpower. For more, see how tirzepatide actually works.

Zepbound vs. Mounjaro: does the brand change your results?

No. Zepbound and Mounjaro are the same drug, tirzepatide, from the same maker, with the same 2.5 mg start and 15 mg top dose. Since August 2026, Mounjaro's label raises the dose only if blood sugar needs more control, while Zepbound's still steps up on a schedule. The full dosing chart covers each step, and Mounjaro results covers the diabetes brand.

What differs is the FDA approval behind each name. Zepbound was approved in November 2023 for chronic weight management, based on SURMOUNT-1. Mounjaro was approved in May 2022 for type 2 diabetes, based on the separate SURPASS trials. The drug in the pen is the same. The brand changes insurance and cost. Zepbound's weight-loss approval gives it a more direct path to coverage. Mounjaro for weight loss usually needs a diabetes diagnosis to get coverage.

Why might your results look different at 45+, in perimenopause?

This has been studied directly. A 2025 analysis of the SURMOUNT trials, published in Obesity, grouped women by stage: before, during and after menopause. All took 15 mg or their highest tolerated dose. In SURMOUNT-1, women before menopause lost about 26% of their weight, against 2% on placebo. Women in perimenopause and after menopause each lost about 23%, against 3% on placebo.

In every group, 97% to 98% of women lost at least 5% of their weight, against 29% to 33% on placebo. The authors concluded tirzepatide worked whatever the stage. So the gap is a few percentage points, not a different response. The study doesn't explain the gap, and the women before menopause were also younger.

One more point for after 40. Fast weight loss on any GLP-1 includes some muscle, not only fat. That matters more when falling estrogen is already working against muscle. Our guide to GLP-1 and muscle loss in perimenopause covers what protects your strength while the weight comes off.

What determines your individual result?

Trial averages explain the shape of the curve. They don't predict your number. A few factors move it in real life:

• The dose you reach and tolerate: SURMOUNT-1 shows about six points between the 5 mg and 15 mg groups.
• Taking it every week: a missed or late shot interrupts the steady drug level these medicines rely on.
• Where you started: starting weight and metabolic health shape how much loss is realistic. That's biology, not a shortfall.
• Your 3-month check: losing at least 5% by then is the marker the trial data tracks. Falling well short is usually when a dose change comes up.
• Things science can't yet explain: some of the spread between low and high responders is still unexplained.

Is a plateau normal, or has it stopped working?

A plateau is normal, and it comes on a fairly predictable schedule. A 2025 analysis of SURMOUNT-1 and SURMOUNT-4 looked at people who took their doses and lost at least 5%. It defined a plateau as less than 5% further change over 12 weeks. Half had plateaued by about 24 to 36 weeks, roughly 6 to 8 months, later at higher starting BMI. By week 72, about 88% to 90% had plateaued. Higher doses, younger age and being female went with a later plateau.

A plateau isn't the drug failing. In the three-year SURMOUNT-1 follow-up, most of the loss held. That's a body settling at a new weight once the dose has been at its top for a while. Weight climbing back up on an unchanged dose is a different pattern, and it isn't what the trials describe as normal.

Does the weight come back if you stop tirzepatide?

For most people, a good part of it does. SURMOUNT-4 took people who had lost about 21% in 36 weeks on tirzepatide. Half kept taking it and half switched to placebo for another year. Those who kept going lost a further 5.5%. Those who stopped regained enough that their weight rose about 14%. Even so, they ended about 10% below where they started, against about 25% for those who stayed on it.

So tirzepatide treats an ongoing condition, the way blood pressure medicine does. Stopping doesn't erase every gain, but your body's old settings come back to a real degree. Factor that in before treating it as a short-term fix.

What does tirzepatide cost, and where do you start?

Price depends on the brand, the dose and your insurance. Without insurance, Lilly sells Zepbound for about $300 to $450 a month by dose, through December 31, 2026. With a commercial plan that covers it, Lilly's savings card can bring it to as little as $25. On Medicare, the GLP-1 Bridge covers the Zepbound KwikPen for $50 a month if you qualify. Compounded tirzepatide costs less at many sellers, but it isn't FDA-approved and is legal only on a narrow basis.